Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds

Page 1 of 4

In this article, we will be taking a look at the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds.

Tom Lee of Fundstrat spoke on CNBC’s Closing Bell on June 9 about chip stocks, market mood, and the overall picture for stocks. According to Lee, investor nervousness ahead of SpaceX’s projected $75 billion IPO and the substantial capital anticipated to be raised by large tech companies like Google, Meta, OpenAI, and Anthropic is reflected in the recent market turbulence. He saw the retreat as a healthy consolidation rather than a danger to the current technological surge in spite of these worries.

Lee pointed out that institutional investors might raise money to take part in the IPO and modify their portfolio positions in response to SpaceX’s anticipated inclusion in the Nasdaq-100. Additionally, he cited memory and semiconductor stocks’ ability to withstand recent lows as proof that the industry’s long-term trend is unaffected by short-term pressure.

In light of this, small-cap stocks have become a significant market topic in 2026. Up 18.6% year-to-date through June 12, the Russell 2000 beat the Dow Jones Industrial Average, Nasdaq, and S&P 500. The index was trading close to a record high in mid-June, according to MarketWatch. However, because many of them are unprofitable and heavily dependent on future cash flows, Reuters reported in May that small-cap companies continue to be especially vulnerable to rising borrowing costs.

In biotechnology, this mix of high risk and significant development potential is particularly noticeable. Small-cap stocks, which are defined as companies with market capitalizations between $300 million and $2 billion, include a number of biotech companies with extremely high analyst upside expectations. According to EY’s 2026 Biotech Beyond Borders report, biotech funding increased 11% to $68.5 billion in 2025. Reuters reported that biotech M&A activity reached $84 billion in the first quarter of 2026, nearly twice as much as the previous year. Positive clinical, regulatory, or acquisition-related developments can therefore significantly increase the value of these businesses.

With that said, let’s now take a look at the most promising stocks on this list.

Our Methodology

For our methodology, we screened for small-cap stocks with market capitalizations between $300 million and $2 billion and analyst price targets implying at least 20% upside potential. From this universe, we selected the 10 best stocks based on their most recent news and corporate developments. We then ranked these companies in ascending order according to the number of hedge funds holding their shares as of Q1 2026, using data tracked by Insider Monkey.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Here is our list of the 10 most promising small-cap stocks to buy according to hedge funds.

10. Prenetics Global Limited (NASDAQ:PRE)

Number of Hedge Fund Holders: 11

Market Cap: $344.98 million

Prenetics Global Limited (NASDAQ:PRE) is one of the most promising stocks on our list.

TheFly reported on June 16 that Benchmark initiated coverage of PRE with a Buy rating and a $30 price target. The firm highlighted the company’s IM8 health and wellness brand, which targets the expanding nutritional supplements market. Benchmark noted that PRE is positioned for long-term growth through broader product offerings, expansion into related categories, diversification of marketing channels, and increasing international market penetration.

On June 10, Prenetics Global Limited (NASDAQ:PRE) reported its first quarter 2026 financial results, highlighted by strong growth from its IM8 health and longevity brand. Total revenue reached $36.0 million, including $33.8 million generated by IM8, representing substantial year-over-year and sequential growth. Encouraged by the brand’s performance, the company increased its full-year 2026 IM8 revenue outlook to between $190 million and $210 million and projected continued momentum for the second quarter.

The business also completed the sale of its digital asset holdings, generating $41.3 million in proceeds. In addition, the company outlined plans to introduce three new IM8 products in the fourth quarter of 2026 and strengthened its leadership team through the appointment of a new chief financial officer for the IM8 business.

Prenetics Global Limited (NASDAQ:PRE) is a health sciences and biotechnology company focused on consumer wellness, preventive genetics, early cancer detection, and longevity solutions, aiming to advance personalized and preventive healthcare.

9. Lands’ End, Inc. (NASDAQ:LE)

Number of Hedge Fund Holders: 11

Market Cap: $382.42 million

Lands’ End, Inc. (NASDAQ:LE) is one of the most promising stocks on our list.

TheFly reported on June 18 that Noble Capital Markets initiated coverage of LE with an Outperform rating and a $20 price target. The firm cited the company’s improved financial position following the repayment of its term loan and highlighted the strategic partnership with WHP Global as a key value driver. According to Noble Capital, the agreement creates opportunities to generate additional value from LE’s brand and intellectual property assets while supporting future growth initiatives.

On June 9, Lands’ End, Inc. (NASDAQ:LE) announced its first-quarter fiscal 2026 financial results. The company reported net revenue of $238.9 million, reflecting a decline from the prior-year period due to temporary disruptions from the implementation of a new warehouse management system and slower shipment activity during distribution center recovery.

Despite the impact, LE noted that revenue would have shown low single-digit growth without the disruption. Net income reached $330.7 million, primarily driven by the WHP Global transaction, while adjusted net loss was $3.5 million. The company also highlighted improved financial flexibility after repaying its term loan and provided updated full-year 2026 guidance for revenue, earnings, and adjusted EBITDA.

Lands’ End, Inc. (NASDAQ:LE) is an American lifestyle retailer offering apparel, swimwear, outerwear, and home products through e-commerce, distribution channels, its Outfitters division, and global licensing partnerships.

Page 1 of 4

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.